EA200400041A1 - Сочетание действующих ингредиентов, используемое в качестве вызывающего привыкание фармакологического средства или для интоксикационной терапии - Google Patents

Сочетание действующих ингредиентов, используемое в качестве вызывающего привыкание фармакологического средства или для интоксикационной терапии

Info

Publication number
EA200400041A1
EA200400041A1 EA200400041A EA200400041A EA200400041A1 EA 200400041 A1 EA200400041 A1 EA 200400041A1 EA 200400041 A EA200400041 A EA 200400041A EA 200400041 A EA200400041 A EA 200400041A EA 200400041 A1 EA200400041 A1 EA 200400041A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination
happening
calling
therapy
pharmacological means
Prior art date
Application number
EA200400041A
Other languages
English (en)
Other versions
EA006647B1 (ru
Inventor
Йохим Моорманн
Херманн Муцке
Клаус Опиц
Original Assignee
Хф Арцнаймиттельфоршунг Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хф Арцнаймиттельфоршунг Гмбх filed Critical Хф Арцнаймиттельфоршунг Гмбх
Publication of EA200400041A1 publication Critical patent/EA200400041A1/ru
Publication of EA006647B1 publication Critical patent/EA006647B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Настоящее изобретение относится к сочетанию действующих ингредиентов, состоящему по меньшей мере из одного модулятора холинергической системы и по меньшей одного вещества, обладающего противовозбуждающим действием, используемому в качестве фармакологического вещества, вызывающего привыкание, или для интоксикационной терапии, в особенности терапии алкоголизма.Отчет о международном поиске был опубликован 2003.09.18.
EA200400041A 2001-06-18 2002-06-15 Сочетание действующих ингредиентов для медикаментозной терапии зависимостей, вызываемых наркотическими или одурманивающими веществами EA006647B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10129265A DE10129265A1 (de) 2001-06-18 2001-06-18 Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
PCT/EP2002/006630 WO2002102388A2 (de) 2001-06-18 2002-06-15 Wirkstoffkombination von z.b. galanthamin oder desoxypeganin mit z.b. acamprosat oder memantin gegen sucht wie z.b. alkoholismus

Publications (2)

Publication Number Publication Date
EA200400041A1 true EA200400041A1 (ru) 2004-04-29
EA006647B1 EA006647B1 (ru) 2006-02-24

Family

ID=7688529

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400041A EA006647B1 (ru) 2001-06-18 2002-06-15 Сочетание действующих ингредиентов для медикаментозной терапии зависимостей, вызываемых наркотическими или одурманивающими веществами

Country Status (28)

Country Link
US (1) US20040192683A1 (ru)
EP (1) EP1397138B1 (ru)
JP (1) JP2005500298A (ru)
KR (1) KR20040010744A (ru)
CN (1) CN1527711A (ru)
AR (1) AR034493A1 (ru)
AT (1) ATE286397T1 (ru)
AU (1) AU2002323873B2 (ru)
BR (1) BR0211008A (ru)
CA (1) CA2450787C (ru)
CZ (1) CZ299951B6 (ru)
DE (2) DE10129265A1 (ru)
EA (1) EA006647B1 (ru)
ES (1) ES2236551T3 (ru)
HK (1) HK1063292A1 (ru)
HU (1) HUP0400865A3 (ru)
IL (2) IL159345A0 (ru)
MX (1) MXPA03011825A (ru)
MY (1) MY129726A (ru)
NO (1) NO20035458D0 (ru)
NZ (1) NZ529944A (ru)
PL (1) PL367207A1 (ru)
PT (1) PT1397138E (ru)
SK (1) SK287180B6 (ru)
TW (1) TWI325320B (ru)
UA (1) UA76753C2 (ru)
WO (1) WO2002102388A2 (ru)
ZA (1) ZA200309232B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
DE10318714B4 (de) * 2003-04-25 2006-03-23 Hf Arzneimittelforschung Gmbh Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE102004048927A1 (de) * 2004-10-06 2006-04-20 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Kombination enthaltend Desoxypeganin und Cyp2D6 Inhibitoren
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
KR101406456B1 (ko) 2005-04-06 2014-06-20 아다마스 파마슈티칼스, 인코포레이티드 Ｃｎｓ 장애의 치료를 위한 방법 및 조성물
DE602006016441D1 (de) * 2005-05-13 2010-10-07 Alza Corp Mehrlagiges arzneimittelausbringsystem mit sperre gegen reservoirmaterialfluss
CN102408548B (zh) 2005-09-01 2013-05-15 布勒公司 聚对苯二甲酸乙二醇酯的制造方法
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
AU2010213683B2 (en) 2009-02-12 2016-04-21 Indiana University Research & Technology Corporation Material and methods for treating developmental disorders including comorbid and idiopathic autism
MX2012006320A (es) 2009-12-02 2013-01-18 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
EP2621487B1 (en) * 2010-09-28 2017-05-03 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
PL3222280T3 (pl) * 2010-12-03 2021-11-29 Nalpropion Pharmaceuticals Llc Wzrost biodostępności leku w terapii naltreksonem
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US10493045B2 (en) * 2016-12-14 2019-12-03 Ru-Band Lu Method for treating alcohol dependence or alcohol abuse
CA3072764A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
BG67408B1 (bg) * 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
DE3843239C1 (ru) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
EP0424179A3 (en) * 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
DE59507585D1 (de) * 1994-10-21 2000-02-10 Sanochemia Pharmazeutika Ag Wi VERFAHREN ZUM HERSTELLEN VON DERIVATEN DES 4a,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO[3a,3,2-ef][2]BENZAZEPINS
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
EP1071655A1 (en) * 1998-04-17 2001-01-31 Kenneth Curry Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus

Also Published As

Publication number Publication date
SK15652003A3 (sk) 2004-04-06
HK1063292A1 (en) 2004-12-24
CA2450787C (en) 2009-06-02
HUP0400865A3 (en) 2011-03-28
CZ299951B6 (cs) 2009-01-07
AU2002323873B2 (en) 2006-11-16
DE50201958D1 (de) 2005-02-10
EA006647B1 (ru) 2006-02-24
CA2450787A1 (en) 2002-12-27
CN1527711A (zh) 2004-09-08
EP1397138B1 (de) 2005-01-05
BR0211008A (pt) 2004-10-26
CZ20033390A3 (en) 2004-03-17
MXPA03011825A (es) 2005-03-07
WO2002102388A2 (de) 2002-12-27
AR034493A1 (es) 2004-02-25
EP1397138A2 (de) 2004-03-17
NO20035458D0 (no) 2003-12-08
PL367207A1 (en) 2005-02-21
NZ529944A (en) 2007-02-23
ES2236551T3 (es) 2005-07-16
MY129726A (en) 2007-04-30
ZA200309232B (en) 2004-07-21
DE10129265A1 (de) 2003-01-02
HUP0400865A2 (hu) 2004-07-28
WO2002102388A3 (de) 2003-09-18
KR20040010744A (ko) 2004-01-31
TWI325320B (en) 2010-06-01
US20040192683A1 (en) 2004-09-30
IL159345A (en) 2009-02-11
JP2005500298A (ja) 2005-01-06
PT1397138E (pt) 2005-04-29
SK287180B6 (sk) 2010-02-08
IL159345A0 (en) 2004-06-01
ATE286397T1 (de) 2005-01-15
UA76753C2 (ru) 2006-09-15

Similar Documents

Publication Publication Date Title
EA200400041A1 (ru) Сочетание действующих ингредиентов, используемое в качестве вызывающего привыкание фармакологического средства или для интоксикационной терапии
ES2195970T3 (es) L-ribavirina y usos de la misma.
BR9911724A (pt) Ciclosporina que tem um perfil de atividade melhorado
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
EA199901031A1 (ru) Производные бензимидазола
ATE277929T1 (de) Immunsuppressive wirkungen von pteridinderivaten
DE69904804D1 (de) Glucocorticoid selektive entzündungshemmende mittel
BR9810495A (pt) Composição farmacêutica
EA199700253A1 (ru) Производные нодулиспоровой кислоты
ES2221950T3 (es) Dihidrobenzofurano y compuestos relacionados utiles como agentes anti-inflamatorios.
BR0002441A (pt) Compostos de hidroxidifenil éter
DE69608414T2 (de) Als insektizid aktive zusammensetzung
BR0207826A (pt) Composições pesticidas contendo ácido oxálico
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
SE9801494D0 (sv) Novel use
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
NO980296L (no) Forbedrede terapeutiske midler
DE69613395D1 (de) Schwefelenthaltende di-ter-butylphenol-verbindungen brauchbar als entzündungshemmende mittel
TR199901017A2 (xx) B�cek ilac� terkibi.
TR199901374T2 (xx) B�cek �ld�r�c� ve mitisidal kompozisyonlar
SE9403137D0 (sv) Derivatives of carbohydrates and compositions containing them
BR9813102A (pt) Derivados de ácido metilenobisfosfÈnico novos
EA200400116A1 (ru) Сочетание действующих веществ для фармакологического лечения никотиновой зависимости

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU